Ian Vessey Managing Director

Has 30+ years of pharma industry experience, including 15 years working in global strategic marketing roles with Novo Nordisk and Novartis, mostly operating at the clinical-commercial interface. This included 4 years as Head of Early Phase Marketing for the Novartis Ophthalmics Business Unit, which provided in-depth exposure to all the major eye care markets, including blepharitis and dry eye. During this time he also led the Lucentis Launch Readiness project for wet AMD across Europe.

He founded Premark Pharma in April 2018 and sits on the Board of Directors.

Friedrich K. Mayer Head of Development, Director

Has 50 years’ experience in the pharmaceutical industry. Starting in the Sandoz Research Institute in Vienna, he moved to corporate headquarters in Basel, Switzerland (now Novartis) as Global Project Leader. He built and led multidisciplinary global project teams taking 6 NMEs from research through registration to life cycle management, including more than 10 years leading the Elidel (pimecrolimus) project in atopic dermatitis.

After retiring from Novartis he has worked as a consultant to small biotechnology firms.

Friedrich has extensive experience in dermatology, infectious diseases and immunology. He holds a Dr. sc. (chemistry) from the University of Technology in Vienna, Austria and an MBA from INSEAD in Fontainebleau, France. He sits on the Board of Directors.

Mark Smithyes Head of Business Development

Has over 25 years of experience in the Pharmaceutical and Medical Device industries. His extensive career includes numerous senior leadership positions in multinationals like Novartis and Alcon as well as founding and serving as President of the successful ophthalmology start up company, Labtician Théa. His expertise includes building and managing businesses, strategic planning and enterprise risk, commercialization, communications and government relations.

He has extensive corporate and nonprofit governance experience having served on Boards of Directors for several organizations including Life Sciences Ontario, Medtech Canada, Labtician Théa, New Circles, and Endeavour Consulting.

Mark holds a BA from Western University, Ontario, Canada and an MBA from the Kellogg School of Management, Northwestern University in Evanston, USA.

Adam Slater Head of Quality

Has 30+ years’ experience in the pharmaceutical/biopharmaceutical industry. Previous roles include senior management positions with Thermo Fisher, Pfizer, J&J, Mylan, MSD and Lonza Biologics. These span Quality Control, Quality Assurance and R&D.

He has supported companies with FDA PAI readiness, EU GMP certification, regulatory compliance, audit and technical transfer.

Adam has extensive experience across dosage forms including steriles, ointments, creams, solid dose, lyophilized powders and ATMPs. He holds a HND BTEC Microbiology, GRSC Analytical Chemistry and Post Graduate Diploma Industrial Pharmaceutical Studies (EU QP Training) Adam is a Fellow of the Royal Society of Biology and Chartered Biologist.

Thomas Mather MD

Oculoplastic surgeon

Eyelid specialist

Kenneth Sall MD

Ophthalmologist

Medical Director, Sall Research Medical Center

Prof. Dr. Thomas Reinhard

Medical Director, Eye Center, University Hospital Freiburg, Germany

Prof. Dr. Daniel Böhringer

Head of Clinical Trials Group, Eye Center, University Hospital Freiburg, Germany

William Stewart MD

Medical Director PRN Pharmaceutical Research Network, LLC

Director PRN PharmaFarm, LLC

Gary Foulks MD

Cornea Consultant